Skip to main content

Newsmakers: Vanderbilt’s teaching, research and patient care efforts are making an impact » Dr. Jeff Conn

Vanderbilt collaborates on Parkinson’s research

Vanderbilt and Bristol-Myers Squibb signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators, or PAMs, for the treatment of Parkinson’s disease. Under the agreement, the Vanderbilt Center for Neuroscience Drug Discovery will identify drug candidates from its existing program, which obtained major support from The Michael J. Fox Foundation for Parkinson’s Research. Bristol-Myers Squibb will have the right to develop and commercialize products resulting from the collaborative research program.


Leave a Response

VIEW MORE EVENTS >